MOREPEN LABORATORIES LTD.

Morepen Laboratories Ltd has announced that its Board of Directors will convene on October 27, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of these financial results, extending to October 29, 2026.

Morepen Laboratories Ltd has received a favorable judgment from the Hon'ble High Court of Himachal Pradesh at Shimla, quashing a Show Cause Notice (SCN) issued by the Central GST & Central Excise Commissionerate, Shimla. The SCN had sought recovery of ₹117,94,03,452/- towards alleged excess GST refund, along with interest and penalty. The High Court's order, received on October 14, 2026, disposed of the writ petition in favor of the company, with no impact on its financials, operations, or other activities.

Morepen Laboratories Ltd has announced the closure of its trading window from October 1, 2026, to facilitate the consideration and approval of its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. During this period, designated persons and their immediate relatives are prohibited from trading in the company's securities. The window will reopen 48 hours after the announcement of the financial results.

Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. This submission marks a significant step in expanding the company's integrated Contract Development and Manufacturing Organization (CDMO) capabilities, moving beyond API to finished dosage development and regulatory filing. The Sitagliptin program encompasses formulation development, scale-up, analytical method validation, stability studies, and GMP manufacturing. This strengthens Morepen's ability to undertake specialized CDMO assignments for regulated markets, including Europe and Asia. The company anticipates a 24-36 month timeline to potential approval and commercial supply, subject to FDA review and other regulatory requirements. Sitagliptin is a treatment for Type 2 diabetes, with its innovator product having recorded substantial sales.

Morepen Laboratories Ltd announced that it received an independent ESG rating of 'CRISIL ESG 60' from Crisil ESG Ratings & Analytics Limited on September 21, 2026. This rating signifies an 'Adequate' category for the company's environmental, social, and governance performance. CRISIL independently assigned this rating based on publicly disclosed information for the fiscal year 2026, without the company's engagement. This provides an external assessment of Morepen Labs' ESG standing.

Morepen Laboratories Ltd has successfully completed the first phase of its manufacturing capacity expansion program ahead of schedule. This expansion increases the company's installed reactor capacity for API and CDMO from 535 KL to 614 KL. The enhanced capacity will support the scale-up of commercial CDMO supplies, bolster the existing API business, and accommodate future customer programs. This milestone is a key part of Morepen's strategy to build a scalable, globally compliant manufacturing platform focused on long-term customer partnerships and sustained growth in its API and CDMO segments.

Morepen Laboratories Ltd has announced its 41st Annual General Meeting (AGM) scheduled for September 26, 2026, to be held via video conferencing. The company has dispatched letters to members without registered email IDs, providing access to the Annual Report for FY 2025-26 through a weblink, QR code, and specified path. The AGM will include electronic voting for resolutions. Additionally, the Board of Directors has proposed a final dividend of ₹0.20 per equity share for FY 2025-26, subject to member approval. Members are reminded to submit requisite tax exemption forms by September 23, 2026, and ensure their KYC is updated for dividend credit, as physical dividend warrants have been discontinued.

Morepen Laboratories Ltd has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, which is an integral part of the Annual Report, details the company's corporate identity, business activities, operations, and employee data. Key business segments include API manufacturing (56.33% turnover) and Medical Devices (35.60%). The company serves over 80 countries, with exports contributing 40% of its total turnover. The BRSR is filed as per SEBI regulations and is available on the company's website.

Morepen Laboratories Ltd has announced its 41st Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, at 1:00 p.m. IST, conducted via Video Conferencing/Other Audio Video Means (VC/OAVM). The meeting will cover ordinary business such as adopting financial statements for FY2025-26 and declaring a final dividend of ₹0.20 per equity share. Special business includes ratifying the remuneration of cost auditors and approving the elevation of Mr. Sanjay Suri from Whole-Time Director to Managing Director. The cut-off date for voting eligibility and the record date for the dividend is September 19, 2026, with remote e-voting commencing on September 23 and ending on September 25, 2026.

Morepen Laboratories Ltd has filed its Annual Report for the financial year 2025-26, along with the notice for its 41st Annual General Meeting (AGM). The AGM is scheduled for September 26, 2026, and will be conducted via Video Conferencing/Other Audio Video Means. The report highlights the company's strategic focus on strengthening its people, technologies, processes, and purpose, serving millions through APIs, formulations, OTC healthcare products, and home diagnostics. It also mentions investments in manufacturing capacity, innovation-led chemistry, digital health, and global partnerships. The company secured a significant multi-year CDMO mandate valued at approximately ₹825 Crore (USD 91 million) from a leading global pharmaceutical company.